secwatch.observer — SEC 8-K summary
======================================

Issuer:     Drugs Made In America Acquisition Corp. (DMAA)
CIK:        0002028614
Form:       8-K
Filed at:   2026-04-08T23:59:59+00:00
Accession:  0001213900-26-041284
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DMAA signs LOI for de-SPAC merger with Power Analytics Global Corp at ~$1B valuation
--------------------------------------------------------------------------------

- Non-binding letter of intent signed April 7, 2026, with target Power Analytics Global Corp (Delaware).
- Implied equity valuation of approximately $1.0 billion, subject to due diligence and adjustments.
- Minimum cash condition expected in range of $25 million to $50 million, subject to redemptions.
- Parties will negotiate definitive business combination agreement; deal to result in PAGC becoming public.
- DMAA may seek stockholder approval to extend business combination deadline; sponsor support possible.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2028614/000121390026041284/0001213900-26-041284-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2028614/000121390026041284/ea0285527-8k_drugs.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-041284

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer